The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
A lot of the posts on this forum confuse me a little bit.
The lack of news from the bod likely means they do not know if this solution is completely valid on a commercial level. Without sufficient data supporting this major investors will not come along. This type of cancer detection is the future of early cancer detection, and the biomarker Cizzle are working on will make up a suite of biomarkers used in the future to detect most cancers in one simple blood test.
The issue is, this is going to be a huge business and there will be many research labs working on a similar solution. Without demonstrating our biomarker is a commercial solution we won’t get any larger companies interested in this.
I think the news that a private investor is investing in the company is great news as it is likely we will need more funding like this in the future to get past the initial trials.
Step 1 which I’m not sure has been proven yet, is can Cizzle create a test that is accurate and consistent - no results from even the first step yet.
Step 2 - larger trials, gathering more data - enough data to prove to larger pharma companies this is a legitimate solution.
Step 3 - commercialisation.
We still have a long way to go, and until there is results from step 1 the bod have very little to talk about, apart from repeating what’s been previously said, with an aim to drum up interest from private investors.
This is what I posted in December 2021, if you think anything major is going to happen this year then you're way off IMO:
So in my opinion, we have 3-5 years of development, followed by a further 2 years to get the product in to mass production.
So real return (if the product is successful) is 5-7 years. For the next 3 years the price will keep dropping until there is real news.
People complain about pharma companies, but in reality they have a lot of potential products, like this, going through development that costs a lot of money, with many failing
As for the funding of this stock, as I said yesterday, the main purpose of this stock is lung cancer detection ($100M-$B market size). Cizzle has invested in AZD1656 to gain royalties from any future sales.
The lung cancer detection hasn't started full scale trials yet. I would imagine the plan of the company is to use the money generated from AZD1656 to fund the lung cancer trials.
Hi All, just thought I'd share some information from a podcast I've been listening to. The podcast is called "Lifespan", and its ran by a guy called David Sinclair. David Andrew Sinclair AO is an Australian biologist who is a professor of genetics and co-director of the Paul F. Glenn Center for Biology of Aging Research at Harvard Medical School. He is known for his research on ageing with a focus on epigenetics.
On episode 5 of the podcast he discusses various "medical interventions", this is mainly different compound/supplements you can take to increase lifespan. But towards the end of the episode he also discusses what the future of disease detection looks like. He said that in the future, you will be able to get a blood test, and the results of the blood test will tell you if you have cancer/disease, and where that cancer is located. This means that the technology that Cizzle are developing will likely be part of a general health blood test, alongside hundreds and maybe thousands of other biomarkers.
This is very long term, but the future of this product is the future of disease detection. Short term this means scanning for people at high risk of lung cancer, but long term is the general health of the global population.
I know you're trying to protect your own investment here, but there is still a long way to go with the development of the product. The upside is huge and I agree with what you're saying but I think timescales are a lot longer than you estimated.
If you're ramping without substance you will get people to invest that become bitter. If they invest after they have understood the company and timescales then they will stick around and support the company long term...
I am currently -75% with my holdings so want this to do well also, but its going to take a lot of time.
So in my opinion, we have 3-5 years of development, followed by a further 2 years to get the product in to mass production.
So real return (if the product is successful) is 5-7 years. For the next 3 years the price will keep dropping until there is real news.
People complain about pharma companies, but in reality they have a lot of potential products, like this, going through development that costs a lot of money, with many failing
I posted this 2nd June 2020:
I think everyone is going to be waiting a long time for any real return from this. If the Tiziana spin out is the target, then looking at what happened to oncotype DX, they listed (as we are wanting to do), this was then followed by 3 years (I think this is correct) of development, then once the product was developed and capable of mass production a larger company will then swoop in to buy the company and the production of the product. We may make a small amount of money in the initial listing, but the big money will be the buyout after years of development. Developing and testing a product like this is one thing, but then getting it ready for production is another. Any thoughts?
I completely agree, at the current price level I see little to no risk in buying right now.
If the deal goes through you make >10% in a year.
If it doesn't go through, you are invested in a very high quality asset, and sell price is likely to be higher than 67.5p.
Am I missing any downsides? If the deal falls through do BCN lose funding etc, which could collapse the price?
If the deal goes ahead at 67.5p, is that what every shareholder is guaranteed to get?
Yeah that makes sense. But if the deal fell through I feel that due to the quality of the asset that 67.5p would be a base level. I think I personally would take 15% over a year
I just have a quick question about the potential buy out, if it goes ahead at 67.5p, will we all lose our shares and get the appropriate value from the sale?
If the takeover value is 67.5p, what is stopping someone buying loads of shares now and making a quick 15%?
Future funding requirements at the bottom of page 14:
https://cizzlebiotechnology.com/app/uploads/2021/05/259313-Project-Balham-Prospectus-LOCKED.pdf
Also details some future options for revenue including the complete sale of the company
Just looking at the RNS they have already raised £2.2 million?
Has there been any details of this placing? Who has put in £2.2 million?
And the placing was at 10p, so someone with a large amount of money is willing to pay more than current market value?
"The Company, following a share reorganisation, completed a placing of 22,000,000 new ordinary shares at 10p per share to raise gross proceeds of £2.2 million. The board intends to apply a majority of the net proceeds of the Placing towards the development of the C1Z1B biomarker test through to CE marking and/or FDA 510(k) clearance."
I haven't had chance to read in to the details in full, but has ongoing funding/financing been discussed? Briefly looking over the prospectus Cizzle has essentially no revenue, so there will be R&D costs, then costs to scale. Will there be an additional share offering? Will an outside company be offered % ownership for funding?
still no announcements on StemPrintER
I never understood SXX, there is another company already operating on the same seem of deposit as the proposed SXX mine (Cleveland Potash), in my mind the guys at SXX were great marketers, that resulted in a lot of people losing a lot of money. Like John said, the cost to entry for an open pit mine is a lot cheaper than SXX. You just need to remember in mining shares there will be a long period of time with little updates, so the share price will come and go, but at the end of the day the mine site here is a great asset with the backing of a big company
Allan*
the housing market in 4-6 months time